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Compound EGFR mutations, deﬁned as double or multiple mutations in the EGFR tyrosine kinase domain,
are frequently detected with advances in sequencing technology but its clinical signiﬁcance is unclear.
This study analyzed 61 cases of EGFR mutation positive lung adenocarcinoma using next-generation
sequencing (NGS) based repeated deep sequencing panel of 16 genes that contain actionable mutations
and investigated clinical implication of compound EGFR mutations. Compound EGFR mutation was
detected in 15 (24.6%) of 61 cases of EGFR mutation-positive lung adenocarcinoma. The majority (12/15)
of compound mutations are combination of the atypical mutation and typical mutations such as exon19
deletion, L858R or G719X substitutions, or exon 20 insertion whereas 3 were combinations of rare atypical
mutations. The patients with compound mutation showed shorter overall survival than those with simple
mutations (83.7 vs. 72.8 mo; P D 0.020, Breslow test). Among the 115 missense mutations discovered in
the tested genes, a few number of actionable mutations were detected irrelevant to the subtype of EGFR
mutations, including ALK rearrangement, BCL2L11 intron 2 deletion, KRAS c.35G>A, PIK3CA c.1633G>A
which are possible target of crizotinib, BH3 mimetics, MEK inhibitors, and PI3K-tyrosine kinase inhibitors,
respectively. 31 missense mutations were detected in the cases with simple mutations whereas 84 in those
with compound mutation, showing that the cases with compound missense mutation have higher burden
of missense mutations (P D 0.001, independent sample t-test). Compound EGFR mutations are detected at
a high frequency using NGS-based repeated deep sequencing. Because patients with compound EGFR
mutations showed poor clinical outcomes, they should be closely monitored during follow-up.
Abbreviations: DFS, disease-free survival; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer; OS,
overall survival; PFS, progression-free survival; TKD, tyrosine kinase domain; TKI, tyrosine kinase inhibitors.
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Introduction
Despite relentless efforts to decrease the mortality of lung can-
cer, it remains a common and leading cause of cancer-related
death worldwide. In the year 2012, 1,824,701 new cases were
identiﬁed and 1,590,000 patients died of lung cancer worldwide
(WHO annual report). During the same period, 21,753 new
Korean cases were diagnosed and 16,654 Korean patients died
of this devastating disease.1
Oncogenic driver mutations include multiple types of geno-
mic changes that are critical for cancer development and main-
tenance. The identiﬁcation of actionable oncogenic driver
mutations that guide selection of appropriate target agents has
improved clinical outcomes of lung cancer patients by incorpo-
rating tumor genotyping into therapeutic decision making.2
Activating EGFRmutations are more frequently identiﬁed in
lung adenocarcinoma in East Asian patients than in other pop-
ulations, and advances in tumor genotyping facilitate discovery
of such mutations in small population samples.3-6 The most
common type of EGFR mutation is in-frame deletion of exon
19 (E19del) around the LREA motif (amino acid residues 747
to 750; »45% of EGFR mutations), followed by L858R point
mutation of exon 21 (»40% of EGFR mutations).7-9 Tumors
with these activating EGFR mutations or less frequent muta-
tions, such as point mutations in exon 18 at position G719
(»3% of EGFR mutations) and the exon 21 L861Q mutant
(»2% of EGFR mutations), show sensitivity to EGFR-tyrosine
kinase inhibitors (TKIs).10-12 On the other hand, in-frame
insertion mutations within exon 20 of EGFR, which account
for 4»10% of all EGFR mutations, and other rare mutations
including L747S, D761Y, T790M, and T854A confer resistance
to EGFR-TKIs.11,13-15
With the clinical application of more sensitive and pre-
cise tumor genotyping systems, rare EGFR mutations of
unknown biological and clinical signiﬁcance are frequently
encountered in routine clinical practice.14,15 Different
responses to EGFR-TKI are reported even for mutations at
the same approximate location within the genomic DNA.
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For example, among the in-frame insertions within EGFR
exon 20, which were originally considered EGFR-TKI resis-
tance mutations with a low response rate (<5%) and short
interval of disease control, A763_Y764insFQEA is now
reported to be a sensitizing mutation to EGFR-TKI.14,15
These ﬁndings indicate that more attention and collabora-
tive efforts are required to elucidate the biological and clini-
cal signiﬁcance of these rare compound mutations.
Compound EGFR mutations are deﬁned as double or multi-
ple independent mutations of the EGFR tyrosine kinase domain
(TKD), in which an EGFR-TKI-sensitizing or other mutation is
identiﬁed together with a mutation of unclariﬁed clinical signiﬁ-
cance.16 Recent advances in tumor genotyping techniques pro-
vide not only accurate data, but also a higher probability of
identifying atypical and multiple mutations in the EGFR-TKD in
a single sample. Kobayashi et al. reported compound EGFR
mutations in which an EGFR-TKI-sensitizing mutation (such as
G719X, E19del, L858R, or L861Q) coexists with uncommon
mutations involving other residues of the EGFR-TKD and show
some sensitivity to EGFR-TKI. In EGFR mutant non-small cell
lung cancer (NSCLC), double mutations in EGFR were detected
in 14»18% of cases using Sanger method based sequencing tech-
niques, but their biologic behavior and clinical signiﬁcance have
not been well characterized.16,17
In this study, we identiﬁed EGFR compound mutations in lung
adenocarcinomas from patients who underwent surgical curative
resection using next-generation sequencing (NGS)-based repeated
deep sequencing of EGFR together with 15 other genes containing
actionable oncogenic mutations. This study shows that the com-
pound EGFR mutation is common in lung adenocarcinoma and
imparts a new meaning of compound EGFR mutation.
Materials and methods
Patient characteristics and tumor DNA samples
A total of 143 patients with a pathologically conﬁrmed diagno-
sis of pStage IB»IIIA lung adenocarcinoma who underwent
curative surgical resection and platinum-based adjuvant che-
motherapy and provided informed consent for tissue collection
were randomly selected from tissue archives of afﬁliated hospi-
tals of Yonsei University Medical Center. Among them, 61
patients with EGFR mutations who had not received EGFR-
TKI before tumor genotyping were enrolled in this study. All
parafﬁn-embedded samples were loaded onto silanated slides
as 4-mm-thick sections. One slide of every block was stained
with H&E and re-examined for the presence of cancer cells.
The enriched area was marked by an independent lung pathol-
ogist to validate the presence of tumor cells. These cancer cell-
enriched areas were microdissected, and DNA was extracted
using a QIAamp DNA FFPE Tissue Kit (Qiagen, Valencia, CA,
USA). Institutional Review Board (IRB) approval was obtained
for this study (IRB #3-2013-0298).
Library preparation, NGS with IonTorrent, and variant
calling
Ten micrograms of genomic DNA were ampliﬁed by the Ion
AmpliSeqTMCustom Panel (Life Technologies, Carlsbad, CA).
This panel contains 16 genes that contain actionable mutations;
AKT1, ALK, BCL2L11, BRAF, DDR2, EGFR, ERBB2, FGFR1,
KRAS, MAP2K1, MET, NRAS, PIK3CA, PTEN, ROS1, and RET.
ALK fusion was detected by FISH using Abbott Vysis ALK break
apart FISH probe kit (Abbott, Abbott Park, Il). Multiplex pools
were puriﬁed with Agencourt AMPure XP beads (Beckman
Coulter Inc.) and ligated with Ion Xpress barcode adapters (Life
Technologies). The fragment size and quantity of each library
were analyzed by a BioAnalyzer using a High Sensitivity Chip
(Agilent, Santa Clara, CA). The library was diluted, and emulsion
PCR was performed with the OnetouchTM reagent kit (Life
Technologies). The emulsion PCR product was enriched using
Dynabeads MyOneTM Streptavidin C1 beads (Life Technolo-
gies). The ﬁnal enriched ion spheres were mixed with a sequenc-
ing primer and polymerase and loaded onto 5 318v2 chips. The
libraries were sequenced with the Ion Torrent PGM sequencer at
deep coverage (aiming for 1,000£) using the Ion OneTouch 200
Template Kit v2 DL and Ion PGM Sequencing 200 Kit v2 with
the 318 v2 chip kits (all from Life Technologies). The sequencing
reads were aligned to the human reference GRCh37 genome,
and base calling was performed using the Ion Torrent Suite
V3.4.2 using tmap-f3 on the Ion Torrent server. The Ion Torrent
Variant Caller (ITVC) v3.4 was used for the detection of muta-
tions, requiring a frequency greater than 5% for a variant to be
called. Bam (Binary sequence Alignment/Map format) and
FASTQ ﬁles (alignment) were generated based on the base call-
ing results and were used to report the variant calling, including
single nucleotide polymorphisms (SNPs) and insertions/deletions
(INDELs).
Statistical analysis
Categorical variables are expressed as percentages and compared
using x2-tests. Differences in distribution of continuous variables
between 2 independent samples were assessed by Mann–Whitney
U test, and the Kaplan–Meier estimator was used for survival
analysis. All analyses were performed with IBM SPSS Statistics
version 20 (IBM Corp). All statistical tests were 2-sided, and a P
value <0.05 was considered to indicate statistical signiﬁcance.
Results
Demographic characteristics of the study population
The 61 patients with mutations in EGFR-TKD had a mean age
of 59 § 9.9 years (range; 34»78 years); 17 (27.9%) were male
and 44 (72.1%) were female. The difference in age at the time
of diagnosis between male and female patients was not signiﬁ-
cant. The majority of patients (50; 82%) did not have a smoking
history, 6 (9.8%) were current smokers, and 5 (8.2%) were ex-
smokers; the ever-smokers had a pack-year average of 43 §
48.2 years. These demographic characteristics are comparable
to previous ﬁndings of EGFR mutation-positive Korean
patients with lung adenocarcinoma.3,4,18
Compound EGFR mutations
Determination of the entire sequence of EGFR exons 18»21
constituting EGFR-TKD revealed that simple mutations were
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the more frequent (46 of 61, 75.4%). These were predominantly
E19del (24 of 61, 39.3%), followed by L858R point mutation
(17 of 61, 27.9%), and EGFR exon 20 insertion mutations (2
out of 61, 3.2%). Point mutations involving exon 20, exon 19
insertions, and L861R were less frequent (Table 1). The remain-
ing 15 cases (24.6%) had compound EGFR mutations, which is
composed of double or multiple independent mutations in the
EGFR-TKD (Table 1). Most of the compound mutations, (10 of
15, 66.7%) were composed of a rare atypical mutation with
EGFR-TKI sensitizing mutations such as G719X (n D 3),
L858R (n D 6), and E19del (n D 1). Interestingly, one case had
a compound mutation composed of L858R and E19del. Two
compound mutations involved exon 20 insertion plus H773Y
and rare cases of E749Q plus A750P, L688F plus G824S, and
multiple point mutations scattered throughout exon 20 and
exon 21 were also detected. The partner mutations were atypi-
cal mutations in exon 18 (V689L, I706T, and E709K), those in
exon 20 (H773Y and R776H), or those in exon 21 (L833V,
H870R, and A871G). Table 1 summarizes the combinations of
speciﬁc mutations detected in this study. Taken together, EGFR
compound mutations are common in EGFR mutation-positive
lung adenocarcinoma.
Clinical characteristics of cases with compound EGFR
mutation
Next, we questioned whether the cases with compound EGFR
mutation showed discernible clinical and pathologic character-
istics (Table 2). There was no difference in age or gender distri-
bution between patients with simple mutation and those with
compound mutation. Smoking status and pStage at the time of
diagnosis were not associated with the type of EGFR mutation.
We also investigated whether the histologic subtype of
adenocarcinoma was different according to the type of muta-
tion. Compound EGFR mutation was not detected in the lepi-
dic predominant types. The subtypes that are associated with
poor clinical outcomes, such as papillary/micropapillary pre-
dominant types and solid with mucin production type, were
more frequently detected in cases with compound mutations
(21.7% vs. 33.3%) but this did not reach clinical signiﬁcance.
The diameter of the tumor mass at the time of operation was
larger in the tumors with compound mutation but also did not
reach statistical signiﬁcance (2.9 § 0.96 vs. 3.4 § 1.01 cm).
Lung adenocarcinoma with compound EGFR mutation
shows poor clinical outcome
Because the cases with compound EGFR mutation had proper-
ties which might be related to poor clinical outcome, we com-
pared the disease-free survival (DFS) and overall survival (OS)
of cases with simple and compound mutations (Fig. 1). The
median follow-up duration of the study population was 81.9
months (95% conﬁdence interval (CI): 65.7»98.1 months). Of
61 patients, 33 (54.1%) experienced recurrence of the disease
and 15 (24.6%) died of same disease during follow-up period.
There was no difference in DFS between the groups, but OS
was signiﬁcantly poorer in the cases with compound mutation
(simple mutation, 83.7 months vs. compound mutation, 72.8
months, P D 0.020, Breslow test) (Fig. 1A). A multivariate anal-
ysis including age, smoking status, EGFR mutation subtypes,
stage, and histologic subtypes revealed that smoking history
(HR, 11.47; 95% CI, 2.510»54.404; P D 0.002), compound
EGFR mutation (HR, 4.030; 95% CI, 1.305»12.446; P D 0.015)
were signiﬁcantly associated with a shorter OS (Table 3). Based
on these ﬁndings, we hypothesized that cases with compound
mutation have a poor response to EGFR-TKI. Among 33
Table 1. Various types of EGFR mutations in exons 18–21 detected by NGS-based repeated deep sequencing.
EGFR mutation type No. % of total
Simple mutations
Exon 19 deletions 24 39.3
Exon 19 insertions V738_K739insKIPVAI 1 1.6
Exon 20 insertions
M766_A767insASV 1 1.6
D770_N771insGCN771T 1 1.6
Exon 20 mutations
N771F 1 1.6
Exon 21 mutations
L858R 17 27.9
L861R 1 1.6
Compound mutations
L858R C V689L 1 1.6
L858R C L833V 1 1.6
L858R C H870R 1 1.6
L858R C A871G 1 1.6
L858R C R776H 1 1.6
L858R C E19del 1 1.6
G719AC I706T 1 1.6
G719S C E709K 1 1.6
G719S C R776H 1 1.6
E19delC I706T 1 1.6
D770_N771insNPY CH773Y 2 3.3
L688F C G824S 1 1.6
E749QC A750P 1 1.6
T785I C Y813H C V845M C V851I C G857R 1 1.6
Total 61 100
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patients that experienced recurrence of lung cancer after cura-
tive resection, 24 had taken EGFR-TKI for management of the
recurrence. However, when the duration of disease control
with EGFR-TKI was analyzed, there was no difference between
groups with compound or simple mutations (data not shown).
To further investigate the reason for the poor clinical
outcome in the cases with compound mutation, we exam-
ined co-mutations in the AKT1, BRAF, DDR2, ERBB2,
FGFR, KRAS, MAPK2K1, MET1, NRAS, PIK3CA, PTEN,
RET, and ROS1 genes, ALK gene rearrangement, and
BCL2L11 intron 2 deletion. A total 115 missense mutations
were discovered in the tested genes (Table 4). 31 missense
mutations were discovered in the cases with simple EGFR
mutations whereas 84 were discovered in those with com-
pound EGFR mutation, showing that the cases with com-
pound EGFR mutation have higher chance of harboring
multiple missense mutations in the clinically important
genes (Table 7) (0.66 mutations / case vs. 6.0 mutations /
case, P D 0.001, independent sample t-test). Similarity the
cases with compound EGFR mutations have higher chance
of co-alteration in the other genes than those with simple
EGFR mutations (0.61 vs. 2.2 genes/case). Interestingly,
there are a few number of actionable mutations irrelevant
to the subtype of EGFR mutations, including ALK rear-
rangement, BCL2L11 intron 2 deletion, KRAS c.35G>A,
PIK3CA c.1633G>A which is possible target mutation of
Table 2. Clinical and pathologic characteristics of the study cases according to subtype of EGFR mutation.
Simple mutation (n D 46) Compound mutation (n D 15) P-value
Age (mean § SD); yrs 59.6 § 10.52 58.9§ 7.93 0.778
Gender
Male 10 7 0.061
Female 36 8
Smoking status
Non-smoker 39 11 0.488
Current smoker 4 2
Ex-smoker 3 2
Stage
IB 4 1 0.970
IIA 16 5
IIB 2 1
IIIA 24 8
Maximum tumor diameter 2.9 § 0.96 3.4 § 1.01 0.075
Histologic subtype
Lepidic predominant 3 0 0.732
Acinar predominant 31 9
Papillary and micropapillary predominant 7 4
Solid with mucin production 3 1
Othersy 2 1
P-value was obtained from t-test
P-value was obtained from Pearson’s Chi-square test
yIncludes invasive mucinous adenocarcinoma and adenosquamous carcinoma
Figure 1. Comparison of overall survival and disease-free survival of patients with lung adenocarcinoma after curative resection according to EGFRmutation type. Kaplan–
Meier estimation was used to compare overall survival (A) and disease-free survival (B) of patients with EGFR mutation-positive lung adenocarcinoma according to EGFR
mutation subtype. Signiﬁcant difference in OS were observed between simple and compound EGFR mutation (simple mutation 83.7 months vs. compound mutation 72.8
months, P D 0.020). P-value was obtained by Breslow test.
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crizotinib, BH3 mimetics, MEK inhibitors, and PI3K-TKIs,
respectively (Tables 5 and 6).19,20 Taken together, the cases
with compound EGFR mutation shows poor OS, which may
attribute to the higher burden of missense mutations in the
clinically important genes.
Discussion
The deﬁnition of a compound EGFR mutation remains as
ambiguous as its clinical signiﬁcance. A compound mutation is
deﬁned as a combination of 2 or more independent mutations
in EGFR-TKD. In the case of E19del, approximately half of the
mutations are accompanied by a continuous, in-frame point
mutation or insertion around the deleted motif. In this study,
these cases were considered simple mutations.
The detection rate of compound EGFRmutations has gradu-
ally increased from 4% in 2004 to 14% in 2013.16,17,21 In a
report from the early era of EGFR sequencing, cDNA of EGFR
exon 18»21 was generated by RT-PCR and used as a template
for sequencing. In that study of Japanese cohorts, 111 of 277
lung adenocarcinomas showed EGFR mutations, and 4 of 111
EGFR mutation-positive cases (4%) were compound EGFR
mutations.21 A study that applied the direct sequencing of
gDNA showed that the frequency of compound mutation in
443 EGFR mutation positive NSCLC is 4.97%.22 Another EGFR
study of a large East Asian cohort sequenced 2 types of speci-
men, gDNA from parafﬁn blocks and total RNA from frozen
tissues. Those studies revealed that, among 627 EGFR muta-
tion-positive cases, 78 (12.4%) were uncommon EGFR
mutations and approximately half of these, 32 cases, were com-
pound EGFR mutations.17 A report that adapted bidirectional
direct DNA sequencing showed that the detection rate of com-
pound EGFR mutation was 14% of total EGFR mutations.16
These differences in the frequency of compound EGFR muta-
tions may be attributed to the progress of sequencing technol-
ogy and the source of sequencing templates. Recent extensive
clinical application of PNA clamping-based EGFR mutation
detection techniques that focus on detection of the G719X,
E19del, T790M, S768I, E20ins3dup, E20ins3, and L858R, or
L861Q mutations showed an increased detection rate of EGFR
mutations. However, compound EGFR mutations were very
rarely encountered in daily practice. This study adopted NGS-
based repeated deep sequencing at exon 18»21 of EGFR, and
the detection rate of compound EGFR mutations was 24.6%.
These technical advances in sequencing provide a higher prob-
ability of encountering EGFR compound mutations.
The majority of compound EGFR mutations are composed
of one typical EGFR mutation and an atypical partner muta-
tion. Point mutations have a higher chance of harboring an
atypical partner mutation. This may be related to the deﬁnition
of a compound EGFR mutation, in which consecutive mutation
around the E19del is deﬁned as a simple mutation. The atypical
partner mutations are quite heterogeneous with respect to loca-
tion in the EGFR gene, and it is difﬁcult to generalize their
effects on EGFR-TKI. A report by Peng et al. showed that
among the 22 cases of the multiple EGFR mutation 20 (90.1%)
had L858R or exon 19 in-frame deletion EGFR mutation.23 The
type of compound EGFR mutation is more homogenous than
our ﬁndings, which showed 7 (46.7%) out of 15 cases accompa-
nied with L858R or exon 19 in frame deletion. In a report by
Kosaka et al., one tumor with a mutation at codon 719 and 3
tumors with mutations at codon 858 contained another muta-
tion at E709H, S768I, R776C, or T790M, respectively.21 This
ﬁnding is similar to that of Wu et al., who showed that all mul-
tiple mutations contained one sensitizing mutation such as
G719X, L858R, L861Q, or E19del and one or more rare atypical
partner mutations. However, the ﬁndings of Kobayashi et al.
and the current study indicate that 20»27% of compound
EGFR mutations consist of rare atypical mutations.16
The concept that one cancer has single driver mutation
is being challenged by the advancement of techniques which
Table 4. Comparisons of nucleotide substitution between EGFR mutation subtypes
in the lung adenocarcinoma.
Substitution
Simple EGFR
mutation (n D 46)
Compound EGFR
mutation (n D 15)
C>T 6 29
A>G 3 0
G>A 17 51
C>G 1 0
G>C 4 2
A>T 0 1
A>C 0 1
Total 31 84
Table 3. Univariate and multivariate analyses for overall survival.
Univariate analysis Multivariate analysis
Variables HR 95% CI P-value HR 95% CI P-value
Age < 65 1 reference – 1 reference –
 65 0.777 0.482-1.251 0.299 1.824 0.628-15.299 0.269
Smoking status None 1 reference – 1 reference –
Current and ex-smoker 3.151 1.087-9.135 0.035 11.47 2.510-52.404 0.002
EGFR subtypes Simple 1 reference – 1 reference –
Compound 2.489 0.925-6.695 0.071 4.030 1.305-12.446 0.015
Stage IB 1 reference – 1 reference –
IIA-IIB 1.717 0.211-13.988 0.614 3.985 0.313-50.713 0.287
IIIA 2.300 0.287-18.41 0.433 9.078 0.743-110.883 0.084
Histologic subtypes Acinar 1 reference – 1 reference –
Papillary and micropapillary 1.229 0.387-3.898 0.726 0.590 0.175-1.985 0.394
Lepidic 1.575 0.357-6.943 0.548 0.890 0.161-4.928 0.894
Solid 0.256 0.012-5.344 0.380 0 – 0.981
Others 0.591 0.028-12.390 0.735 0 – 0.988
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are capable of sequencing multiple genes at a time. When
the frequency of the co-alteration of EGFR and ALK rear-
rangement was evaluated by EGFR direct sequencing and
ALK FISH, it is 0.27%.24 When the EGFR mutations status
was re-inspected in ALK rearrangement positive and EGFR
mutation negative cases with the mutant enriched NGS, the
co-mutation rate was increased up to 15.4%.24 Another
study that investigated mutation of PIK3CA exon 9 and 20
in 1,117 NSCLC showed that it was detected in 3.9% of
squamous cell cancer and 2.7% of adenocarcinoma.25
Among 34 NSCLC cases that have PIK3CA mutation, 17
cases had co-mutation in the EGFR exon 18»21 and 4 cases
in the KRAS exon 2»3 showing PIK3CA mutation is fre-
quently accompanied with EGFR/KRAS mutation.25 In our
study, ALK rearrangement and PIK3CA was observed in 3
cases respectively, suggesting that the representative driver
mutations are not completely mutually exclusive and can
occasionally be found at lower frequently. It is worthy of
notice that MET had highest mutational burden among the
genes tested in this panel. However, no mutation was
detected in the exon14 and exon skipping could not be
detected by the applied technique.26,27 Mutations in the
MET kinase domain (c.3166-c.4068; Exon 15»21) were
detected in the 8 cases, but their biologic signiﬁcance is not
conﬁrmed yet.
A few papers have reported that there are differences in
the responses to the EGFR-TKIs among compound EGFR
mutations. Peng et al. revealed that when the clinical out-
come between NSCLC patients with L858 single mutation
and those with L858 and other co-mutation in EGFR exon
Table 5. Mutations detected in the lung adenocarcinoma with simple EGFR mutation.
Rand No. ALK BCL2L11 BRAF FGFR1 KRAS MET NRAS PIK3CA ROS1 RET
E0006
E0010
E0016 c.2143A>G
E0017 Rearrangement c.3437G>A c.2071G>A
E0019
E0023 c.2071G>A
E0024
E0033 c.5326G>C c.2071G>A
E0043 Int 2 del
E0051
E0059 Int 2 del
E0081
E0098 c.2071G>A
E0108 Rearrangement Int 2 del
E0110 Int 2 del c.3637C>T
E0116
E0120
E0123 Int 2 del c.1750C>T c.1456C>T c.109G>A c.2379G>A c.91G>A c.1633G>A c.2071G>A
E0124 c.5326G>C
E0126
E0130
E0138 Int 2 del c.5326G>C
E0149
E0152 c.2071G>A
E0157
E0168
E0174 c.35G>A
E0182
E0187
E0191
E0195
E0197 c.3496C>T,
c.3503A>G
E0201
E0203 c.1766C>T c.3503A>G
E0210 c.3836C>T c.2071G>A
E0222
E0224
E0226
E0233 c.2071G>A
E0242
E0250 c.1255G>A
E0252 c.2208C>G
E0256 Int 2 del c.5704G>A,
c.5326G>C
E0260 c.2071G>A
E0269
E0272
Actionable mutations (19).
BCL2L11 intron 2 deletion mutant (20).
yNo mutation was detected in AKT1, DDR2, ERBB2, MAP2K1, and PTEN.
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18»21 was compared, there was no signiﬁcant differences
in OS and PFS.22 Another study addressed the clinical sig-
niﬁcance of compound EGFR mutations, showing a poorer
outcome for patients with rare atypical mutations combined
with E19del or L858R (progression-free survival (PFS) 5.3
months, OS 18.8 months) compared with those with single
classic mutations (PFS 8.5, OS 19.6 months).17 Compound
mutations that contain sensitizing mutations such as G719X
or L858R seem to have good responses to EGFR-TKIs. On
the other hands, those comprised of rare atypical mutations
have poor response to EGFR-TKI.17,28 In our study, a
homogenous cohort was selected to identify the clinical
meaning of compound mutations, and we found that
patients with compound EGFR mutations had poorer OS
than those with simple EGFR mutations. It is of note that
there was no difference in the DFS. These ﬁndings suggest
that mutation status may be related to the response to drug
administered after conﬁrmation of recurrence. The
unproved supposition that tumors with a compound EGFR
mutation do not respond to EGFR-TKI might cause clini-
cians to hesitate in positioning EGFR-TKI at the early line
of therapy, which may have complicated evaluation of the
response to EGFR-TKI in this study cohort. Several other
factors such as male predominance, larger tumor size at the
time of detection, and aggressive histologic subtype might
have acted in combination to inﬂuence the poor OS of
patients with the compound EGFR mutation.
The biologic signiﬁcance of co-alteration of EGFR and other
genes need to be investigated. In a study that evaluated the
response to TKIs in the 14 NSCLC which had EGFR and ALK
co-alteration, 3 treated with EGFR-TKI showed poor responses
to geﬁtinib but 8 treated with ALK inhibitors revealed favorable
responses, suggesting that signaling from ALK rearrangement
override EGFR.24 Others addressed the importance of PIK3CA
mutation test by showing that the patients with PIK3CA single
mutation showed poorer prognosis than those with co-muta-
tion of PIK3CA and EGFR/KRAS.25
A few mutations in the BCL2L11, ALK, PIK3CA, and KRAS
are key driver mutations that can be potentially targeted, while
those in the other genes need further validation. It would be
interesting to see if the NSCLC patients with EGFR compound
mutation or co-alteration with other genes may be beneﬁt from
3rd generation EGFR-TKIs when compared to 1st and 2nd gen-
eration EGFR-TKIs.29,30
In conclusion, compound EGFR mutation is frequently
detected in EGFR-mutant tumors and is related to poor
overall survival of patients with lung adenocarcinoma.
Because it is expected that such mutations may be more fre-
quently detected with wider adoption of NGS-based tests,
more dedicated efforts are needed to clarify their biologic
effects on disease course and drug responsiveness.
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